AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla

Roche's Tecentriq gains new first-line lung cancer use

Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients. 

Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer. 

Blueprint pays the price of Ayvakit phase 3 miss as FDA reje...

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received the

AZ/Merck & Co's Lynparza sets 'new standards' in ovarian can...

AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data.